Published: 7 May 2012Medical InformationProduct Announcements

Significantly enhances market access to Cysview in the US market

Oslo, Norway, May 7, 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today approval by the US FDA of the upgraded Karl Storz blue light cystoscopy equipment for use in combination with Photocure's flagship product Cysview for the improved detection of bladder cancer.

This approval marks a significant milestone for Photocure's commercialization of Cysview in the US and paves the way for a significant increase in market access. The launch of Cysview by Photocure's own commercial operations was initiated in January 2012 and the approval of the upgraded equipment will enable the placement of further blue light cystoscopes in leading urology centres across the US.

Cysview (hexaminolevulinate hydrochloride), the first significant advance for the improved detection of bladder cancer, was approved for use in combination with the blue light cystoscopy equipment (Karl Storz D-Light C PDD System) in May 2010. After the initial approval, an upgrade to enhance the blue light system, which corresponds to the version on the market in Europe, was filed to the FDA by Karl Storz Endoscopy America.

Kjetil Hestdal, President and CEO of Photocure said: "We are delighted that our collaborator, Karl Storz Endoscopy America, has received approval of its upgraded blue light cystoscopy equipment. We are confident that this will drive an increase in number of hospitals obtaining the blue light cystoscopy equipment and therefore drive the increased use of Cysview. We look forward to working closely with Karl Storz to bring Cysview Photodynamic Diagnosis to many more bladder cancer patients in the US."

For further information, please contact:
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:

Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email:

About Cysview

Cysview/Hexvix (hexaminolevulinate hydrochloride) is the first approved drug-device procedure for improved detection of bladder cancer. It is designed to induce fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect non muscle invasive bladder cancer, as an adjunct to white light cystoscopy. The product is used in combination with a blue light cystoscopy system It is the first product in a new diagnostic class known as photodynamic diagnostic (PDD) agents.

Bladder cancer is the fourth most common type of cancer in men and the eighth most common in women in the US. More than 70,000 people in the US were diagnosed with cancer of the bladder in 2009, with an estimated 14,000 people dying from the disease, according to the National Cancer Institute. In Europe, bladder cancer is the seventh most common type of cancer in men and the fourteenth in women. Each year in Europe, approximately 36,500 men and 13,000 women die due bladder cancer. It is notoriously difficult to detect. The most common, initial sign is blood in the urine, which calls for urine cytology and cystoscopy.

About Photocure ASA

Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Cysview/Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology.

Allumera®, Photocure® and Cysview®/Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit

Important Risk and Safety Information about Cysview (hexaminolevulinate HCl)

INDICATIONS: Cysview is an optical imaging agent for use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder in patients with known or suspected lesion(s) on the basis of a prior cystoscopy. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system for blue light cystoscopy as an adjunct to the white light setting. Limitations - Cysview is not a replacement for random biopsies or other procedures used in the detection of bladder cancer. It is not for repeat use; the potential risks associated with repetitive exposure have not been studied. CONTRAINDICATIONS: Cysview is contraindicated in patients with porphyria, gross hematuria, BCG immunotherapy or intravesical chemotherapy within 90 days prior, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. WARNINGS AND PRECAUTIONS: Anaphylaxis: Anaphylaxis, including anaphylactoid shock, has been reported following administration of Cysview. Failed Detection - Cysview may fail to detect some bladder tumors, including malignant lesions. False Fluorescence: Fluorescent areas detected during blue light cystoscopy may result from inflammation, cystoscopic trauma, scar tissue or bladder mucosal biopsy from a previous cystoscopic examination. Urine and/or blood within the bladder may interfere with the detection of tissue fluorescence. ADVERSE REACTIONS: Clinical Study Experience: The most common adverse reactions were bladder spasm, dysuria, hematuria, and bladder pain. Postmarketing Experience: Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis and abnormal urinalysis have been reported. USE IN SPECIFIC POPULATIONS: Pregnancy: Cysview should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers: It is not known whether hexaminolevulinate is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when Cysview is administered to nursing mothers. Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: No clinically important differences in safety or efficacy have been observed between older and younger patients.

Prior to Cysview administration, please read the Full Prescribing Information

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events